Skip to content

Study · Animal study (in vivo) · mouse · 2015

9 results

Carnosine markedly ameliorates H9N2 swine influenza virus-induced acute lung injury.

Xu T, Wang C, Zhang R, Xu M, Liu B, Wei D, Wang G, Tian S

The Journal of general virology31 Jul 2015Cited by 22 (Europe PMC)

PMID26233716 (opens in a new tab)PMCIDPMC4635477 (opens in a new tab)DOI10.1099/jgv.0.000238 (opens in a new tab)PepBankPUB-26233716
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In H9N2-infected mice, carnosine decreased mortality to 43% versus 75% in the H9N2 group.

    In plain wordsIn H9N2-infected mice, mortality was 43% with carnosine versus 75% without carnosine.

    Peptide
    L-carnosine
    Outcome
    DecreaseMortality
    Study

    mousen: not reported in source

    H9N2 influenza-induced acute lung injury
    Comparator
    H9N2 group
    Outcome group
    Mortality · Respiratory
    Studied dose
    10 mg/kg body mass · oral · 7 daysAs given in this study (mouse).

    Measurements

    Mortality
    43%
    carnosine
    Mortality
    75%
    H9N2 group

    Source sentences

    Summary
    Carnosine treatment effectively decreased the mortality (43 versus 75 %, P < 0.05), significantly ameliorated pathological lesions in lungs and decreased the lung wet/dry mass ratio (P < 0.05).
    2 context sentences
    Summary · context
    Female specific-pathogen-free BALB/c mice were randomized into four groups and treated as follows: (1) H9N2 group, (2) mock control group, (3) H9N2+carnosine group and (4) carnosine control group.
    Summary · context
    Carnosine [10 mg (kg body mass)- 1] was administered orally (100 μl) for 7 days consecutively.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In H9N2-infected mice, carnosine significantly ameliorated lung pathological lesions compared with the H9N2 group.

    In plain wordsIn H9N2-infected mice, carnosine significantly reduced lung damage compared with the H9N2 group.

    Peptide
    L-carnosine
    Outcome
    DecreaseLung pathological lesions
    Study

    mousen: not reported in source

    H9N2 influenza-induced acute lung injury
    Comparator
    H9N2 group
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    10 mg/kg body mass · oral · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    Carnosine treatment effectively decreased the mortality (43 versus 75 %, P < 0.05), significantly ameliorated pathological lesions in lungs and decreased the lung wet/dry mass ratio (P < 0.05).
    2 context sentences
    Summary · context
    Female specific-pathogen-free BALB/c mice were randomized into four groups and treated as follows: (1) H9N2 group, (2) mock control group, (3) H9N2+carnosine group and (4) carnosine control group.
    Summary · context
    Carnosine [10 mg (kg body mass)- 1] was administered orally (100 μl) for 7 days consecutively.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In H9N2-infected mice, carnosine decreased lung wet/dry mass ratio compared with the H9N2 group.

    In plain wordsIn H9N2-infected mice, carnosine decreased the lung wet/dry mass ratio compared with the H9N2 group.

    Peptide
    L-carnosine
    Outcome
    DecreaseLung wet/dry mass ratio
    Study

    mousen: not reported in source

    H9N2 influenza-induced acute lung injury
    Comparator
    H9N2 group
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    10 mg/kg body mass · oral · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    Carnosine treatment effectively decreased the mortality (43 versus 75 %, P < 0.05), significantly ameliorated pathological lesions in lungs and decreased the lung wet/dry mass ratio (P < 0.05).
    2 context sentences
    Summary · context
    Female specific-pathogen-free BALB/c mice were randomized into four groups and treated as follows: (1) H9N2 group, (2) mock control group, (3) H9N2+carnosine group and (4) carnosine control group.
    Summary · context
    Carnosine [10 mg (kg body mass)- 1] was administered orally (100 μl) for 7 days consecutively.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In H9N2-infected mice, carnosine inhibited lung MPO activity compared with the H9N2 group.

    In plain wordsIn H9N2-infected mice, carnosine reduced lung MPO activity compared with the H9N2 group.

    Peptide
    L-carnosine
    Outcome
    DecreaseMPO activity
    Study

    mousen: not reported in source

    H9N2 influenza-induced acute lung injury
    Comparator
    H9N2 group
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    10 mg/kg body mass · oral · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    It also inhibited MPO activity, suppressed TNF-α and IL-1β release, decreased the H9N2 viral titre, and markedly inhibited levels of TLR-4 mRNA and protein in the lungs of infected mice (P < 0.05), which supported the use of carnosine for managing severe influenza cases.
    2 context sentences
    Summary · context
    Female specific-pathogen-free BALB/c mice were randomized into four groups and treated as follows: (1) H9N2 group, (2) mock control group, (3) H9N2+carnosine group and (4) carnosine control group.
    Summary · context
    Carnosine [10 mg (kg body mass)- 1] was administered orally (100 μl) for 7 days consecutively.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In H9N2-infected mice, carnosine suppressed TNF-α release compared with the H9N2 group.

    In plain wordsIn H9N2-infected mice, carnosine reduced TNF-α release compared with the H9N2 group.

    Peptide
    L-carnosine
    Outcome
    DecreaseTNF-α release
    Study

    mousen: not reported in source

    H9N2 influenza-induced acute lung injury
    Comparator
    H9N2 group
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    10 mg/kg body mass · oral · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    It also inhibited MPO activity, suppressed TNF-α and IL-1β release, decreased the H9N2 viral titre, and markedly inhibited levels of TLR-4 mRNA and protein in the lungs of infected mice (P < 0.05), which supported the use of carnosine for managing severe influenza cases.
    2 context sentences
    Summary · context
    Female specific-pathogen-free BALB/c mice were randomized into four groups and treated as follows: (1) H9N2 group, (2) mock control group, (3) H9N2+carnosine group and (4) carnosine control group.
    Summary · context
    Carnosine [10 mg (kg body mass)- 1] was administered orally (100 μl) for 7 days consecutively.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In H9N2-infected mice, carnosine suppressed IL-1β release compared with the H9N2 group.

    In plain wordsIn H9N2-infected mice, carnosine reduced IL-1β release compared with the H9N2 group.

    Peptide
    L-carnosine
    Outcome
    DecreaseIL-1β release
    Study

    mousen: not reported in source

    H9N2 influenza-induced acute lung injury
    Comparator
    H9N2 group
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    10 mg/kg body mass · oral · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    It also inhibited MPO activity, suppressed TNF-α and IL-1β release, decreased the H9N2 viral titre, and markedly inhibited levels of TLR-4 mRNA and protein in the lungs of infected mice (P < 0.05), which supported the use of carnosine for managing severe influenza cases.
    2 context sentences
    Summary · context
    Female specific-pathogen-free BALB/c mice were randomized into four groups and treated as follows: (1) H9N2 group, (2) mock control group, (3) H9N2+carnosine group and (4) carnosine control group.
    Summary · context
    Carnosine [10 mg (kg body mass)- 1] was administered orally (100 μl) for 7 days consecutively.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In H9N2-infected mice, carnosine decreased viral titre compared with the H9N2 group.

    In plain wordsIn H9N2-infected mice, carnosine decreased viral levels compared with the H9N2 group.

    Peptide
    L-carnosine
    Outcome
    DecreaseH9N2 viral titre
    Study

    mousen: not reported in source

    H9N2 influenza-induced acute lung injury
    Comparator
    H9N2 group
    Outcome group
    Antiviral activity · Respiratory
    Studied dose
    10 mg/kg body mass · oral · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    It also inhibited MPO activity, suppressed TNF-α and IL-1β release, decreased the H9N2 viral titre, and markedly inhibited levels of TLR-4 mRNA and protein in the lungs of infected mice (P < 0.05), which supported the use of carnosine for managing severe influenza cases.
    2 context sentences
    Summary · context
    Female specific-pathogen-free BALB/c mice were randomized into four groups and treated as follows: (1) H9N2 group, (2) mock control group, (3) H9N2+carnosine group and (4) carnosine control group.
    Summary · context
    Carnosine [10 mg (kg body mass)- 1] was administered orally (100 μl) for 7 days consecutively.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In H9N2-infected mice, carnosine inhibited lung TLR-4 mRNA levels compared with the H9N2 group.

    In plain wordsIn H9N2-infected mice, carnosine reduced lung TLR-4 mRNA levels compared with the H9N2 group.

    Peptide
    L-carnosine
    Outcome
    DecreaseLung TLR-4 mRNA
    Study

    mousen: not reported in source

    H9N2 influenza-induced acute lung injury
    Comparator
    H9N2 group
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    10 mg/kg body mass · oral · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    It also inhibited MPO activity, suppressed TNF-α and IL-1β release, decreased the H9N2 viral titre, and markedly inhibited levels of TLR-4 mRNA and protein in the lungs of infected mice (P < 0.05), which supported the use of carnosine for managing severe influenza cases.
    2 context sentences
    Summary · context
    Female specific-pathogen-free BALB/c mice were randomized into four groups and treated as follows: (1) H9N2 group, (2) mock control group, (3) H9N2+carnosine group and (4) carnosine control group.
    Summary · context
    Carnosine [10 mg (kg body mass)- 1] was administered orally (100 μl) for 7 days consecutively.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In H9N2-infected mice, carnosine inhibited lung TLR-4 protein levels compared with the H9N2 group.

    In plain wordsIn H9N2-infected mice, carnosine reduced lung TLR-4 protein levels compared with the H9N2 group.

    Peptide
    L-carnosine
    Outcome
    DecreaseLung TLR-4 protein
    Study

    mousen: not reported in source

    H9N2 influenza-induced acute lung injury
    Comparator
    H9N2 group
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    10 mg/kg body mass · oral · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    It also inhibited MPO activity, suppressed TNF-α and IL-1β release, decreased the H9N2 viral titre, and markedly inhibited levels of TLR-4 mRNA and protein in the lungs of infected mice (P < 0.05), which supported the use of carnosine for managing severe influenza cases.
    2 context sentences
    Summary · context
    Female specific-pathogen-free BALB/c mice were randomized into four groups and treated as follows: (1) H9N2 group, (2) mock control group, (3) H9N2+carnosine group and (4) carnosine control group.
    Summary · context
    Carnosine [10 mg (kg body mass)- 1] was administered orally (100 μl) for 7 days consecutively.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.